



Revvity Accelerates NGS Library Prep with Introduction of New Fontus Automated Liquid Handling Workstation at 2023 AACC

7/20/2023

- Fontus' easy-to-use software, optimized deck access, verified NGS protocols and reformatting capabilities simplify workflows and improve turnaround times
- Enables nearly any liquid handling application to be automated
- Revvity will showcase additional industry-leading diagnostic solutions at 2023 AACC

WALTHAM, Mass.--(BUSINESS WIRE)-- **Revvity** (NYSE: RVTY), today announced the launch of the **Fontus™ Automated Liquid Handling Workstation**, a next-generation liquid handler incorporating the best technologies from Revvity's existing platforms, designed to deliver easier and faster workflows which enable better results for next generation sequencing (NGS) and diagnostic research applications.

An Upgraded Automation Workstation Founded on Well-Established Technologies

The Fontus workstation features streamlined software, tube-to-plate reformatting, 96 or 384 array head with partial tip loading and integrated peripherals, such as on-deck thermocycler, temperature modules and up to two labware grippers. The system provides improved usability compared to existing Revvity platforms, offering users greater deck access and ergonomics, and an improved enclosure.

Available in a pre-configured NGS model, the Fontus workstation is designed to support fast and accurate NGS library prep automation using proven, vendor-qualified automated methods. The easy-to-use software and access to Revvity's dedicated support team of automated liquid handling and NGS application experts are provided so users can reduce start up time, optimize their workflows and focus on the science. To support environmental sustainability, the separate waste chutes for recyclables and biohazard waste allow users to easily separate the two, and the workstation integrates extra labware storage without additional footprint to remove the need for an

external robot or more bench space.

“The growth of NGS demands consistent quality library prep and higher throughput,” said Yves Dubaquier, Revvity’s senior vice president, diagnostics. “The Fontus workstation was designed to meet these expectations with pre-developed methods based on models developed and perfected by our experts over the past 35 years. It’s well suited for a wide range of liquid handling applications and will be especially valuable in this climate where supply of talented lab personnel is limited while more work needs to be accomplished in a timely manner.”

Available globally for pharmaceutical and biotechnology companies, contract research organizations (CROs), diagnostic labs, academia and governments, Revvity is in the process of obtaining IVDR registration for the Fontus workstation with shipments beginning imminently.

More Solutions Front and Center at 2023 AACC

Alongside the Fontus workstation, a series of other solutions will also be presented by Revvity, including some under its **EUROIMMUN** brand, at the 2023 AACC Annual Scientific Meeting and Clinical Lab Expo from July 25-27 in Anaheim, California. These diagnostics solutions located at booth #3251 include:

- The EUROIMMUN UNIQO™ 160 automated indirect immunofluorescence test system for detection of autoimmune diseases;
- The Revvity BioQule™ NGS System, a fully automated, open-chemistry, walkaway sample preparation system for constructing up to eight libraries simultaneously, with in-built QC and quantitation; and
- The HIVE CLX™ scRNAseq Solution that expands the frontiers of single cell research for studies in innate immunology, infectious disease and other clinical research applications.

Additionally, the Company will have a poster presentation focused on **high-precision T cell testing** and several others within clinical and diagnostic immunology at the conference on July 26.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2022 revenue of more than \$3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has

customers in more than 190 countries.

Stay updated by following our **Newsroom, LinkedIn, Twitter, YouTube, Facebook** and **Instagram**.

Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Source: Revvity